A breakthrough tool may help doctors monitor prostate cancer more accurately and slow treatment resistance.
Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a promising new imaging probe designed to improve how prostate cancer is tracked—and potentially treated.
The probe, called ARi-FL, resists breakdown in the body and can “light up” androgen receptors (AR) in cancer cells. These receptors play a central role in driving tumor growth. By making them easier to see, the tool may allow doctors to monitor changes in tumors over time and guide more effective treatment decisions.
Why this matters
Prostate cancer is the most common cancer among U.S. men and the second-leading cause of cancer-related deaths, according to the National Cancer Institute. In 2025, the disease is expected to account for more than 15% of all new cancer cases.
Current therapies often target androgen receptors, but many patients eventually develop resistance, leading to a more aggressive and lethal stage of the disease known as castrate-resistant prostate cancer.
“Being able to track AR over time could help doctors choose the right treatment sooner and more effectively,” said Sheryl Roberts, Ph.D., assistant professor of oncology at Wayne State University School of Medicine and lead investigator of the study.
A closer look at the new probe
Unlike earlier compounds, ARi-FL is stable, highly visible under fluorescent imaging, and works even when androgen receptors mutate. That reliability could make it a valuable clinical tool for detecting cancer progression and adjusting treatment strategies before resistance fully develops.
“This tool could help track AR in patients and guide better treatment choices,” Roberts explained.
The research team, including Christopher Kelly, Ph.D., professor of physics and astronomy at Wayne State, is now using computational modeling to refine the probe’s chemistry and explore next-generation versions, including radioligand-based approaches.
Funding and publication
The study, titled High-Affinity Probes for Androgen Receptor Imaging: From Cells and In Silico Modeling to Whole-Body Fluorescent Applications, was published in the Journal of Medicinal Chemistry. The project received support from the National Institutes of Health, the Karmanos Cancer Center Initiative, and Wayne State University.
YOU MAY ALSO LIKE
